Search Results

You are looking at 1 - 10 of 20 items for :

  • "Germ cell cancer" x
Clear All
Full access

Kim Margolin

-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer . Ann Intern Med 1977 ; 87 : 293 – 298 . 2 International Germ Cell Cancer Collaborative Group . International germ cell consensus classification: A prognostic

Full access

2005 3 3 1 1 45 45 51 51 10.6004/jnccn.2005.0003 Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis Margolin Kim MD 1 2005 3 3 1 1 77 77 83 83 10.6004/jnccn.2005.0004 Controversies in the Surgical Management of

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld and Jue Wang

good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council . J Clin Oncol 2001 ; 19 : 1629 – 1640 . 10

Full access

Eleni Efstathiou and Christopher J. Logothetis

. Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

lung metastasis; and determining the presence of brain or bone metastasis if suspicious clinical symptoms are present. Risk Classification for Advanced Disease In 1997, the International Germ Cell Cancer Consensus Group (IGCCCG) defined a

Full access

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld and Darren R. Feldman

surveillance in patients with clinical stage I disease, provided that patients are asymptomatic. The American Joint Committee on Cancer (AJCC) stages for testicular cancer and The International Germ Cell Cancer Collaborative Group (IGCCCG) classification of

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang and Richard B. Wilder

-HCG, symptoms related to disseminated disease, and a testicular mass, chemotherapy can be initiated immediately without waiting for a biopsy diagnosis. Risk Classification for Advanced Disease In 1997, the International Germ Cell Cancer Consensus Group

Full access

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller and Lenora A. Pluchino

Nonseminoma Stage IIA,” page 1541, and TEST-B, pages 1541–1543). Advanced Metastatic Nonseminoma The primary chemotherapy options for patients with advanced metastatic nonseminoma are based on the International Germ Cell Cancer Consensus Group (IGCCCG) risk

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard and Lois B. Travis

criteria defined by the International Germ Cell Cancer Consensus Classification Group. 33 Patients with low-risk disease generally receive 3 cycles of BEP or 4 cycles of EP. For patients with intermediate- or high-risk disease, the standard therapy is 4

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa and Lois B. Travis

TC according to the International Germ Cell Cancer Collaborative Group (IGCCCG) typically receive BEPX3 or EPX4, whereas those with intermediate- or high-risk disease receive BEPX4 or etoposide/ifosfamide/cisplatin (VIPX4). 14 Approximately 20% of